GET DAILY SIGNALSVolitionRx (VNRX): What the $14 Analyst Target Implies for This Micro-Cap Stock
Key Takeaways
- The central $14 stock price target is the arithmetic mean of the verified analyst price targets reviewed (about $13.62, rounded), drawn from a group of roughly five covering analysts.
- VolitionRx Limited (VNRX), a multinational epigenetics diagnostics company, trades near $0.19, so reaching $14 would require an extraordinarily large move of more than 7,000%.
- The analyst target range is exceptionally wide — roughly $2 to $24 — reflecting deep disagreement about the commercial potential of the company's Nu.Q and Capture-Seq platforms.
- Bullish cases rest on liquid-biopsy data, partnerships with major diagnostics firms, and early reimbursement progress in France; the principal risks are persistent losses, cash burn, and heavy dilution.
- The stock completed a 1-for-20 reverse split in April 2026 and remains a distressed micro-cap with negative earnings per share (EPS).
- For more on this ticker, explore its Major News and Today's Price Move, review the Forecast, and check upcoming Earnings pages.
Analyst Price Targets and Consensus View
VolitionRx Limited (VNRX) is followed by a small number of brokers, and their price targets are unusually scattered. Across the targets reviewed, the figures span from roughly $2 on the cautious end to $24 at the top, a spread that reflects genuine disagreement about whether the company's diagnostics can reach commercial scale. The arithmetic mean of the verified targets is approximately $13.62, which rounds to a $14 central target used here.
Sentiment leans bullish on balance, with most covering analysts at Buy or the equivalent of a Moderate Buy and at least one at Hold. On the optimistic side, JonesTrading has published a $24 target, citing an under-recognized Nu.Q platform and expanding clinical applications, while H.C. Wainwright has carried a Buy rating near $20, pointing to revenue growth and early Capture-Seq data. D. Boral Capital moved to a Hold in 2026, reflecting caution about near-term commercial traction. The low end of the range, near $2, illustrates how dramatically views diverge on the same business. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
This is not a guarantee of where the stock will trade. The wide range is itself the key message: analysts agree that the company holds potentially valuable science but disagree sharply on how quickly, or whether, that value can be monetized.
Current Market Position and Path Toward the Target
The stock trades at roughly $0.19, giving VolitionRx Limited (VNRX) a market capitalization of only about $5.8 million. Moving to $14 would require a gain of more than 7,000% — an extraordinarily large move that would effectively reprice the company from a distressed micro-cap into a far higher valuation tier. That is a reflection of how far the shares have fallen after the April 2026 1-for-20 reverse split, not of a typical analyst scenario.
Fundamentals remain pre-commercial. Trailing twelve-month revenue was about $2.46 million against a net loss of roughly $26 million, with diluted EPS around negative $3.80. The path to any higher valuation runs through converting clinical and licensing momentum — such as the Nu.Q NETs sepsis assay, the Capture-Seq liquid-biopsy technology, and veterinary testing — into recurring, reimbursed revenue.
What Could Support a Move Toward the Target
The strongest evidence is scientific and partnership-driven rather than financial. The company's Capture-Seq method has reported high sensitivity in detecting early-stage cancers, including a blinded cohort in which 95% of stage I and II cancers were detected. Its Nu.Q NETs H3.1 assay is the sole biomarker in the French government-backed DETECSEPS sepsis study, and the company is pursuing a lung-cancer reimbursement dossier with Hospices Civils de Lyon in France. From what I see, these milestones could prove important if they translate into revenue.
Commercial relationships also matter. VolitionRx Limited (VNRX) has collaborated with Sysmex to optimize the Nu.Q NETs assay, worked with Fujifilm Vet Systems on automated veterinary testing in Japan, and co-markets with Revvity in Europe. First-quarter 2026 revenue of about $1 million represented roughly 300% year-over-year growth, and a pending feline lymphoma publication could trigger a $5 million milestone payment.
What Could Prevent the Target From Being Reached
The principal obstacle is financial sustainability. The company is unprofitable, generated negative operating cash flow, and has relied on equity sales through an at-the-market facility, a convertible note, and a public offering of shares and warrants — all of which dilute existing holders. The reverse split itself was undertaken to regain NYSE American listing compliance, underscoring balance-sheet pressure.
Commercial risk is also material. Reimbursement decisions can be delayed or denied, licensing discussions may not convert to signed agreements, and VolitionRx Limited (VNRX) competes in liquid biopsy against much larger, better-capitalized diagnostic companies. With only a small revenue base, any setback in clinical timelines or regulatory reviews could further pressure the shares.
Technical Levels and Market Structure
The shares have been in a pronounced downtrend following the reverse split. The reported 52-week range spans from $0.16 to $9.60, and the stock trades near the lower end of that range. The $0.16 area represents the nearest meaningful support, while any recovery would first need to reclaim levels well above the current price before a move of the magnitude implied by the $14 target could begin to form. The post-split history offers little durable resistance framework at higher prices because the shares have not sustained a base there.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may differ. For VolitionRx Limited (VNRX), the most relevant upcoming catalysts include quarterly earnings and cash-burn disclosures, the feline lymphoma publication and associated milestone payment, progress on the French lung-cancer reimbursement dossier, the launch of the DETECSEPS sepsis study, and any announced licensing or partnership agreements. Share-count changes and capital raises should also be watched closely, given their direct effect on per-share value. I’m watching this closely as these events unfold.
Exploring AI Daily Buy/Sell Signals
In my own research, I often rely on Tickeron's AI Daily Buy/Sell Signals to track automated Buy, Sell, or Hold indications across thousands of stocks and ETFs. The tool draws on shifting market conditions, technical behavior, and AI-driven analysis to help identify trends more efficiently than manual screening alone. For a volatile micro-cap such as VolitionRx Limited (VNRX), where sentiment and technicals can shift quickly, this adds a useful automated perspective alongside fundamental work.
Final Assessment
The $14 central target is best understood as a mathematical midpoint of widely divergent analyst views rather than a consensus expectation. Reaching it from roughly $0.19 would demand a move of more than 7,000%, which is not a typical outcome and reflects both the stock's distressed micro-cap status and the speculative, high-upside nature of the analyst targets themselves. The bull case is grounded in compelling early clinical data and credible partnerships, while the bear case centers on persistent losses, ongoing dilution, and unproven commercialization. With targets ranging from about $2 to $24, investors should treat the wide dispersion — not the single rounded figure — as the clearest signal of uncertainty, and monitor cash burn, reimbursement progress, and licensing execution in the quarters ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VNRX's RSI Indicator ascending out of oversold territory
The RSI Indicator for VNRX moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 26 of the 35 cases the stock moved higher. This puts the odds of a move higher at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VNRX advanced for three days, in 146 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 46 cases where VNRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNRX as a result. In 90 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
VNRX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VNRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.183) is normal, around the industry mean (4.142). P/E Ratio (-0.051) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a development stage life sciences company
Industry MedicalNursingServices
Advertisement